Drug Profile
Ad26 Mos HIV trivalent vaccine - Janssen Vaccines and Prevention B.V
Alternative Names: Ad26 Mos HIV; Ad26 Mos HIV + clade C gp140; Ad26 mosaic vector + gp140; Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Ad26.Mos.HIV + gp140; Adenovirus-serotype-26-Mosaic-HIV-vaccine; Adenovirus-serotype-26-Mosaic-HIV-vaccine + Clade C glycoprotein 140; HIV Px Vaccine; JNJ-9220Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Crucell Holland
- Developer Beth Israel Deaconess Medical Center; International AIDS Vaccine Initiative; Janssen Vaccines and Prevention B.V; Johnson & Johnson; U.S. Military HIV Research Program
- Class AIDS vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III HIV infections
Most Recent Events
- 07 Sep 2022 (Phase-III development is ongoing in USA and Europe (Johnson & Johnson pipeline, September 2022)
- 25 Apr 2022 Janssen Vaccines and Prevention B.V completes a phase-II clinical trial in HIV infections (Prevention) in USA (IM) (NCT02788045)
- 01 Mar 2022 Janssen Vaccines & Prevention B.V. completes a phase-I/II clinical trials in HIV infections (Prevention) in USA, Uganda, Thailand, South Africa, Rwanda (IM) (NCT02315703)